Lotus Pharmaceutical Co., Ltd.

  - A New Drug Development Company

Background

Lotus Pharmaceutical Co., Ltd. (called as Lotus), founded in 1988 in Taiwan, is a technology-based and marketing-driven specialty pharmaceutical company.  Lotus was founded as a marketing agent for other international pharmaceutical companies.  Since Lotus acquired a pharmaceutical manufacturing plant in early 90’s, Lotus started to dedicate its development work in difficult generics, such as sustained release tablet, soft capsule and patch products and then to market its own products in Taiwan.

In 1994, Lotus successfully launched its first product, Mesyrel, in China.  With the promotion experience with Watson Pharmaceuticals in China, Lotus has set up its branch office in Shanghai, China to distribute Lotus’ products and other future license-in products.

Lotus is mainly selling its products to general hospitals, medical centers and clinics in Taiwan.  The revenue in 2008 was 18 million USD with an expectation to grow at least 10% per year.  Being the top 10 pharmaceutical manufacturer in Taiwan, Lotus understands the market in Taiwan is very limited and highly competitive, and thus Lotus is actively seeking export or out-licensing opportunities in highly regulated regions, such as US, Europe and Japan.  Lotus has prepared several product submission dossiers and is ready for plant facility inspections to fulfill different country regulations.

Now Lotus has filed one ANDA with the US FDA and has several ANDA candidates are yet to be collaborated with potential partners.  In the meantime, Lotus starts its business development in the ASEAN countries.  Lotus expects to receive a good return on revenues in the next few years.

The philosophy of Lotus in these years remains developing difficult generics to let patients have inexpensive quality products to use.  Currently Lotus has two cGMP production units, one for normal solid dosage form, cream, nasal spray, and another one for the hormonal products.  A new independent unit is yet to be constructed in the end of 2009 specializing oncology products.

Lotus expects to be listed publicly in Taiwan in 2010. With the encouragements and expectations from the shareholders, Lotus shall commit more to the human health and to the society.